Skip to content
Screener

Cogent Biosciences, Inc. COGT Q3 2025 earnings

Reported November 7, 2025 · Before market open

EPS-$0.50Beat by $0.04
EPS estimate-$0.54

Next report

Aug 10, 2026 (In 3 days)
Revenue estimate$1.0K
EPS estimate-$0.55

Financials

Q3 2025

Income statement

See full
Operating income-$83.4M-10.5%
Net income-$80.9M-14.6%
EPS (diluted)-$0.50+3.8%

Balance sheet

See full
Cash & equivalents$125.3M+29.1%
Total debt$60.6M+240%
Total equity$302.5M-3.9%
Total assets$425.9M+10.9%

Cash flow

See full
Operating cash flow-$64.3M-23.7%
CapEx$65.0K-76.8%
Free cash flow-$64.4M-23.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.01B+69.7%
Enterprise value$1.94B+76.0%

Returns & leverage

See full
Return on equity-95.4%+26.2pp
Debt / equity0.2×+0.1×
Current ratio6.4×-0.1×

FAQ

When did Cogent Biosciences, Inc. report Q3 2025 earnings?
Cogent Biosciences, Inc. (COGT) reported Q3 2025 earnings on November 7, 2025 before market open.
What were Cogent Biosciences, Inc.'s Q3 2025 revenue and EPS?
Cogent Biosciences, Inc. reported eps of $-0.50 for Q3 2025.
Did Cogent Biosciences, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.54 by $0.04.
How did Cogent Biosciences, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 21.9% from $-0.64.
Where can I find Cogent Biosciences, Inc.'s Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001193125-25-272334) directly on SEC EDGAR. The filing index links above go to sec.gov.